Abstract
In the present study we aimed to demonstrate the efficacy of short-term pretreatment with finasteride in patients undergoing transurethral resection of the prostate (TUR-P). For this purpose 40 patients with BPH, who were candidates for TUR-P, were randomized into two groups. The first group (n=20) received 5 mg finasteride/day for 4 weeks prior to surgery and the second group (n=20) remained as the control. Patients who underwent prior prostate or urethral surgery and had a diagnosis of prostate cancer or chronic renal failure, patients who received finasteride, aspirin, coumadin or similar anticoagulant drugs prior to surgery and patients who had capsule perforations or open sinuses during the surgery were excluded from the study. All patients had a normal digital rectal examination and PSA values less than 4 ng/ml. As we look at the results there was no statistically significant difference between the finasteride group and control group regarding age, IPSS, PSA, prostate volumes, preoperative serum hemoglobin, hematocrit values and mean operating times and used irrigating fluids. The total amount of bleeding and bleeding per gram resected tissue were significantly lower in the finasteride group regardless of prostate volume. Furthermore the decrease in the hemoglobin and hematocrit values was higher in the control group. As a conclusion four weeks of finasteride pretreatment provided a significant decrease in peroperative bleeding regardless of prostate volume without any major side effects.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Mebust WK, Holtgrewe HL, Cockett ATK, Peters PC . Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluation of 3885 patients. J Urol 1989; 141: 243–247.
Melchior J, Valk WL, Foret JD, Mebust WK . Transurethral prostatectomy: computerized analysis of 2223 consecutive cases. J Urol 1974; 112: 634–642.
Lissbrant IF, Haggstrom S, Damber JE, Bergh A . Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 1998; 139: 451–456.
Lekas E et al. Decrement of blood flow precedes the involution of the ventral prostate in the rat after castration. Urol Res 1997; 25: 309–314.
Shabsigh A et al. Rapid reduction in blood flow to the rat ventral prostate after castration: preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival. Prostate 1998; 36: 201–216.
Carlin BI, Bodner DR, Spinnak JP, Resnick MI . Role of finasteride in the treatment of hematuria secondary to benign prostatic hyperplasia. Prostate 1997; 31: 180–182.
Puchner PJ, Miller MI . The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report. J Urol 1995; 154: 1779–1782.
Sieber PR et al. The treatment of gross hematuria secondary to prostatic bleeding with finasteride. J Urol 1998; 159: 1232–1233.
Joseph IB, Nelson JB, Denmeade SR, Isaacs JT . Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 1997; 3: 2507–2511.
Haggstrom S, Lissbrant IF, Bergh A, Damber JE . Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats. J Urol 1999; 161: 1620–1625.
Bailey DM, Foley SJ . Microvascular anatomy in patients with recurrent hematuria related to prostatic hypertrophy (BPH). J Urol 1999; 161: 865 (abstract).
Levine AC et al. Androgens induce the expression of the vascular endothelial growth factors in human fetal prostatic fibroblasts. Endocrinology 1998; 139: 4672–4678.
Kashif KM, Foley SJ, Basketter V, Holmes SA . Haematuria associated with BPH-Natural history and a new treatment option. Prostate Cancer Prostatic Dis 1998; 1: 154–156.
Ekengren J, Hahn RG . Blood loss during transurethral resection of the prostate as measured by the hemocue photometer. Scand J Urol 1993; 27: 501–517.
Gormley GJ et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Eng J Med 1992; 327: 1185–1191.
Stoner E . The clinical effects of 5α-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group. J Urol 1992; 147: 1298–1302.
Saez C et al. Expression of basic fibroblast growth factors and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride. Prostate 1999; 40: 83–88.
Monti S et al. Prevalent decrease of the EGF content in the periurethral zone of BPH tissue induced by the treatment with finasteride or flutamide. J Androl 1997; 18: 488–494.
Schwartz Jr S et al. Androgen-independent basal cell re-epithelialization, c-erbB-2 mRNA expression and androgen-dependant EGFr mRNA expression in benign prostatic hyperplasia explant cultures treated with finasteride. Int J Cancer 1998; 76: 519–522.
Moon S-Y, Moon W-C, Choi HR, Gi Y-J . Finasteride inhibits angiogenesis and expression of VEGF in human BPH. J Urol 1998; 159: 332 (abstract).
Bailey DM, Foley SJ, Wedderburn A . effect of finasteride on microvessel density (MVD) in patients with recurrent haematuria related to prostatic hypertrophy (BPH). J Urol (suppl) 1999; (abstract).
Hagerty JA, Ginsberg PC, Harmon JD, Harkaway RC . Pretreatment with finasteride decreases perioperative bleeding associated with transurethral resection of the prostate. Urology 2000; 55: 684–689.
Sandfeldt L, Bailey DM, Hahn RG . Blood loss during transurethral resection of the prostate after 3 months of treatment with finasteride. Urology 2001; 58: 972–976.
Donohue JF et al. Transurethral resection and bleeding: a randomized, placebo controlled trial of the role of finasteride for decreasing operative blood loss. J Urol 2002; 168: 2024–2026.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Özdal, Ö., Özden, C., Benli, K. et al. Effect of short-term finasteride therapy on peroperative bleeding in patients who were candidates for transurethral resection of the prostate (TUR-P): a randomized controlled study. Prostate Cancer Prostatic Dis 8, 215–218 (2005). https://doi.org/10.1038/sj.pcan.4500818
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.pcan.4500818
Keywords
This article is cited by
-
The effect of short-term use of finasteride versus cyproterone acetate on perioperative blood loss with monopolar transurethral resection of prostate
African Journal of Urology (2021)
-
Impact of preoperative 5α-reductase inhibitors on perioperative blood loss in patients with benign prostatic hyperplasia: a meta-analysis of randomized controlled trials
BMC Urology (2015)
-
Role of 5α-reductase inhibitors in benign prostatic diseases
Prostate Cancer and Prostatic Diseases (2012)
-
A systematic review of the effects and mechanisms of preoperative 5α-reductase inhibitors on intraoperative haemorrhage during surgery for benign prostatic hyperplasia
Asian Journal of Andrology (2011)
-
Prevention and management of TURP-related hemorrhage
Nature Reviews Urology (2011)